Efficacy and safety of catheter ablation with vein of Marshall ethanol infusion in patients with persistent AF and HFrEF

Cheng,Shilin; Yin,Jie; Li,Xinran; Wang,Yu; Hu,Hesheng

doi:10.3892/br.2025.2031

Efficacy and safety of catheter ablation with vein of Marshall ethanol infusion in patients with persistent AF and HFrEF

Authors:
- Shilin Cheng
- Jie Yin
- Xinran Li
- Yu Wang
- Hesheng Hu
View Affiliations

Affiliations: Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250000, P.R. China, Department of Cardiology, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial QianFoshan Hospital, Jinan, Shandong 250014, P.R. China, Department of Cardiology, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial QianFoshan Hospital, Jinan, Shandong 250014, P.R. China
Published online on: July 17, 2025 https://doi.org/10.3892/br.2025.2031
Article Number: 153
Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Atrial fibrillation (AF) is a common arrhythmia that usually coexists with heart failure (HF). However, research into the efficacy and safety of catheter ablation with vein of Marshall ethanol infusion (VOM‑EI) in patients with persistent AF and HF with reduced ejection fraction (HFrEF) is limited. In the present study, a single‑center retrospective study was conducted, involving 85 patients with persistent AF and HFrEF. Patients in group A (n=40; male/female: 29/11; average age: 62.33±11.50 years) received catheter ablation plus VOM‑EI treatment, while patients in group B (n=45; male/female: 34/11; average age: 59.36±10.91 years) received catheter ablation only. The study compared the two groups regarding primary endpoint events (rate of restoration of sinus rhythm after surgery and rate of postoperative AF recurrence) and secondary endpoint events [cardiac function parameters (left ventricular ejection fraction (LVEF), left atrium diameter (LAD), left ventricular end diastolic volume (LVEDV)], New York Heart Association (NYHA) classification, B‑type natriuretic peptide (BNP) and rate of postoperative rehospitalization] at 6 months of follow‑up. Surgery duration and perioperative adverse events were also compared between the two groups. There were no statistical differences in baseline characteristics, CHA2DS2‑VASc score and HAS‑BLED score between the two groups. In comparison with group B, group A had a decreased rate of postoperative AF recurrence (2.78 vs. 21.05%). Compared with preoperative levels, both groups achieved significant enhancement in postoperative LVEF, LVEDV and LAD. Group A exhibited a significantly greater improvement in postoperative LVEF, NYHA classification and BNP levels compared with group B. No significant differences were observed between the two groups in the rate of sinus rhythm restoration (90.0 vs. 84.44%) and the rate of postoperative rehospitalization (2.78 vs. 15.79). In addition, group A exhibited a significantly shorter surgical duration than group B (156.78±39.36 min vs. 181.73±52.39 min). There were no statistically significant differences in the rate of perioperative adverse events between the two groups (7.5 vs. 8.89%). In summary, the use of VOM‑EI in conjunction with catheter ablation is a safe and effective strategy for treating patients with persistent AF and HFrEF. This approach results in effective cardiac function restoration, lower postoperative AF recurrence rate, and shorter surgical time.

View Figures

View References

1	Brundel BJJM, Ai X, Hills MT, Kuipers MF, Lip GYH and de Groot NMS: Atrial fibrillation. Nat Rev Dis Primers. 8(21)2022.PubMed/NCBI View Article : Google Scholar
2	Baman JR and Passman RS: Atrial Fibrillation. JAMA. 325(2218)2021.PubMed/NCBI View Article : Google Scholar
3	Tsigkas G, Apostolos A, Despotopoulos S, Vasilagkos G, Kallergis E, Leventopoulos G, Mplani V and Davlouros P: Heart failure and atrial fibrillation: New concepts in pathophysiology, management, and future directions. Heart Fail Rev. 27:1201–1210. 2022.PubMed/NCBI View Article : Google Scholar
4	Carlisle MA, Fudim M, DeVore AD and Piccini JP: Heart failure and atrial fibrillation, like fire and fury. JACC Heart Fail. 7:447–456. 2019.PubMed/NCBI View Article : Google Scholar
5	Bidaoui G, Assaf A and Marrouche N: Atrial fibrillation in heart failure: Novel insights, challenges, and treatment opportunities. Curr Heart Fail Rep. 22(3)2024.PubMed/NCBI View Article : Google Scholar
6	Mundisugih J, Franke KB, Tully PJ, Munawar DA, Kumar S and Mahajan R: Prevalence and prognostic implication of atrial fibrillation in heart failure subtypes: Systematic review and meta-analysis. Heart Lung Circ. 32:666–677. 2023.PubMed/NCBI View Article : Google Scholar
7	Kotecha D, Chudasama R, Lane DA, Kirchhof P and Lip GY: Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol. 203:660–666. 2016.PubMed/NCBI View Article : Google Scholar
8	Becher N, Metzner A, Toennis T, Kirchhof P and Schnabel RB: Atrial fibrillation burden: A new outcome predictor and therapeutic target. Eur Heart J. 45:2824–2838. 2024.PubMed/NCBI View Article : Google Scholar
9	Parkash R, Wells GA, Rouleau J, Talajic M, Essebag V, Skanes A, Wilton SB, Verma A, Healey JS, Sterns L, et al: Randomized ablation-based Rhythm-Control versus rate-control trial in patients with heart failure and atrial fibrillation: Results from the RAFT-AF trial. Circulation. 145:1693–1704. 2022.PubMed/NCBI View Article : Google Scholar
10	Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, Poole JE, Bahnson TD, Lee KL and Mark DB: CABANA Investigators. Ablation versus drug therapy for atrial fibrillation in heart failure: Results From the CABANA trial. Circulation. 143:1377–1390. 2021.PubMed/NCBI View Article : Google Scholar
11	Parameswaran R, Al-Kaisey AM and Kalman JM: Catheter ablation for atrial fibrillation: Current indications and evolving technologies. Nat Rev Cardiol. 18:210–225. 2021.PubMed/NCBI View Article : Google Scholar
12	Rodriguez-Manero M, Schurmann P and Valderrabano M: Ligament and vein of marshall: A therapeutic opportunity in atrial fibrillation. Heart Rhythm. 13:593–601. 2016.PubMed/NCBI View Article : Google Scholar
13	O'Neill L, De Becker B, De Smet M, Francois C, Tavernier R, Duytschaever M, Le Polain De Waroux JB and Knecht S: Vein of marshall ethanol infusion for AF Ablation; A review. J Clin Med. 13(2438)2024.PubMed/NCBI View Article : Google Scholar
14	Lador A and Valderrabano M: Atrial fibrillation ablation using vein of marshall ethanol infusion. Methodist Debakey Cardiovasc J. 17:52–55. 2021.PubMed/NCBI View Article : Google Scholar
15	Valderrabano M, Peterson LE, Swarup V, Schurmann PA, Makkar A, Doshi RN, DeLurgio D, Athill CA, Ellenbogen KA, Natale A, et al: Effect of catheter ablation with vein of marshall ethanol infusion vs catheter ablation alone on persistent atrial fibrillation: The VENUS randomized clinical trial. JAMA. 324:1620–1628. 2020.PubMed/NCBI View Article : Google Scholar
16	Derval N, Duchateau J, Denis A, Ramirez FD, Mahida S, André C, Krisai P, Nakatani Y, Kitamura T, Takigawa M, et al: Marshall bundle elimination, Pulmonary vein isolation, and line completion for ANatomical ablation of persistent atrial fibrillation (Marshall-PLAN): Prospective, single-center study. Heart Rhythm. 18:529–537. 2021.PubMed/NCBI View Article : Google Scholar
17	Lai Y, Liu X, Sang C, Long D, Li M, Ge W, Liu X, Lu Z, Guo Q, Jiang C, et al: Effectiveness of ethanol infusion into the vein of marshall combined with a fixed anatomical ablation strategy (the ‘upgraded 2C3L’ approach) for catheter ablation of persistent atrial fibrillation. J Cardiovasc Electrophysiol. 32:1849–1856. 2021.PubMed/NCBI View Article : Google Scholar
18	Bruggmann C, Astaneh M, Lu H, Tozzi P, Ltaief Z, Voirol P and Sadeghipour F: Management of atrial fibrillation following cardiac surgery: Observational study and development of a standardized protocol. Ann Pharmacother. 55:830–838. 2021.PubMed/NCBI View Article : Google Scholar
19	Tiver KD, Quah J, Lahiri A, Ganesan AN and McGavigan AD: Atrial fibrillation burden: An update-the need for a CHA2DS2-VASc-AFBurden score. Europace. 23:665–673. 2021.PubMed/NCBI View Article : Google Scholar
20	Zhu W, He W, Guo L, Wang X and Hong K: The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: A systematic review and meta-analysis. Clin Cardiol. 38:555–561. 2015.PubMed/NCBI View Article : Google Scholar
21	Krisai P, Pambrun T, Nakatani Y, Nakashima T, Takagi T, Kamakura T, Andre C, Cheniti G, Tixier R, Chauvel R, et al: How to perform ethanol ablation of the vein of marshall for treatment of atrial fibrillation. Heart Rhythm. 18:1083–1087. 2021.PubMed/NCBI View Article : Google Scholar
22	Wood KA and Barnes AH: Variations in follow-up after atrial fibrillation ablation. J Am Assoc Nurse Pract. 33:602–610. 2020.PubMed/NCBI View Article : Google Scholar
23	Wood KA, Barnes AH, Paul S, Hines KA and Jackson KP: Symptom challenges after atrial fibrillation ablation. Heart Lung. 46:425–431. 2017.PubMed/NCBI View Article : Google Scholar
24	Valderrábano M, Liu X, Sasaridis C, Sidhu J, Little S and Khoury DS: Ethanol infusion in the vein of marshall: Adjunctive effects during ablation of atrial fibrillation. Heart Rhythm. 6:1552–1558. 2009.PubMed/NCBI View Article : Google Scholar
25	Takigawa M, Vlachos K, Martin CA, Bourier F, Denis A, Kitamura T, Cheniti G, Lam A, Martin R, Frontera A, et al: Acute and mid-term outcome of ethanol infusion of vein of marshall for the treatment of perimitral flutter. Europace. 22:1252–1260. 2020.PubMed/NCBI View Article : Google Scholar
26	Kamakura T, Andre C, Duchateau J, Nakashima T, Nakatani Y, Takagi T, Krisai P, Ascione C, Balbo C, Tixier R, et al: Distribution of atrial low voltage induced by vein of Marshall ethanol infusion. J Cardiovasc Electrophysiol. 33:1687–1693. 2022.PubMed/NCBI View Article : Google Scholar
27	Gao MY, Sang CH, Huang LH, Lai YW, Guo Q, Liu XX, Zuo S, Li CY, Wang W, Guo XY, et al: Vein of marshall ethanol infusion: First-step or adjunctive choice for perimitral atrial tachycardia? Pacing Clin Electrophysiol. 46:20–30. 2023.PubMed/NCBI View Article : Google Scholar
28	Benali K, Khairy P, Hammache N, Petzl A, Da Costa A, Verma A, Andrade JG and Macle L: Procedure-related complications of catheter ablation for atrial fibrillation. J Am Coll Cardiol. 81:2089–2099. 2023.PubMed/NCBI View Article : Google Scholar
29	Xiao FY, Ju WZ, Chen HW, Huang WJ and Chen M: A comparative study of pericardial effusion and pleural effusion after cryoballoon ablation or radiofrequency catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 31:1062–1067. 2020.PubMed/NCBI View Article : Google Scholar
30	Kamakura T, Derval N, Duchateau J, Nakashima T, Cochet H, Sacher F, Hocini M, Jais P, Haïssaguerre M and Pambrun T: Incidence of vein of marshall stenosis after ethanol infusion: Is repeated ethanol infusion feasible? JACC Clin Electrophysiol. 7:953–954. 2021.PubMed/NCBI View Article : Google Scholar
31	Liu CM, Lo LW, Lin YJ, Lin CY, Chang SL, Chung FP, Chao TF, Hu YF, Tuan TC, Liao JN, et al: Long-term efficacy and safety of adjunctive ethanol infusion into the vein of marshall during catheter ablation for nonparoxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 30:1215–1228. 2019.PubMed/NCBI View Article : Google Scholar
32	Gillis K, O'Neill L, Wielandts JY, Hilfiker G, Almorad A, Lycke M, El Haddad M, le Polain Waroux de JB, Tavernier R, Duytschaever M and Knecht S: Vein of marshall ethanol infusion as first step for mitral isthmus linear ablation. JACC Clin Electrophysiol. 8:367–376. 2022.PubMed/NCBI View Article : Google Scholar
33	He B, Zhao F, Yu W, Li Y, Wu X and Lu Z: Ethanol infusion of vein of marshall for the treatment of persistent atrial fibrillation: The basics and clinical practice. J Cardiovasc Dev Dis. 9(270)2022.PubMed/NCBI View Article : Google Scholar
34	Nattel S: Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation. JACC Clin Electrophysiol. 3:425–435. 2017.PubMed/NCBI View Article : Google Scholar
35	Sohns C and Marrouche NF: Atrial fibrillation and cardiac fibrosis. Eur Heart J. 41:1123–1131. 2020.PubMed/NCBI View Article : Google Scholar
36	Reddy YNV, Borlaug BA and Gersh BJ: Management of atrial fibrillation across the spectrum of heart failure with preserved and reduced ejection fraction. Circulation. 146:339–357. 2022.PubMed/NCBI View Article : Google Scholar